- Doribax™ (doripenem for injection) [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc, October 2007. Available at http://www.doribax.com/doribax/interactive_pi.html; accessed April 8, 2008.
- Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005;11 (12): 974–984.
- Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49 (9): 3944–3947.
- Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48 (8): 3136–3140.
- Jones RN, Huynh HK, Biedenback DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54 (1): 144–154.
- Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004;48 (4): 1384–1396.
- Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005;49 (10): 4413–4417.
- Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52 (1): 71–74.
- Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48 (8): 3086–3092.
- Opal SM. Molecular mechanisms of antibiotic resistance in bacteria. In Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 6th ed. New York: Elsevier/Churchill Livingstone, 2005.
- Chambers HF. Carbapenems. In Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 6th ed. New York: Elsevier/Churchill Livingstone, 2005.
- Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006;59 (4): 220–228.
- Solomkin J, Umeh O, Jiang J, Kaniga K, Friedland I. Doripenem versus meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections. Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17–20, 2007, Chicago, IL.
- Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K. Treatment of complicated intra-abdominal infections: doripenem versus meropenem. Int J Antimicrob Agents 2007;29 (Suppl 2): S212.
- Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27–30, 2006, San Francisco, CA.
- Naber K, Redman R, Kotey P, Llorens L, Kaniga K. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis. Int J Antimicrob Agents 2007;29 (Suppl 2): S212.
- Rea-Neto A, Niederman M, Lee M, Kaniga K, Prokocimer P, Friedland I. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17–20, 2007, Chicago, IL.
- Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of doripenem versus imipenem for ventilator-associated pneumonia. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17–20, 2007, Chicago, IL.
- Lister PD. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther 2007;5 (5): 793–809.
- Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006;222 (1–2): 114–124.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 21, 2008 - Issue 3